ArticleThoracic cancer2014
Lung cancer incidence and mortality in China, 2010.
Article in Thoracic cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Honokiol combined with curcumin sensitizes multidrug-resistant human lung adenocarcinoma A549/DDP cells to cisplatin.Experimental and therapeutic medicine · 2021Article
- Bag-1 Silence Sensitizes Non-Small Cell Lung Cancer Cells To Cisplatin Through Multiple Gene Pathways.OncoTargets and therapy · 2019Article
- [China National Lung Cancer Screening Guideline with Low-dose Computed Tomography (2018 version)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2018Article
- Short-term inpatient-based high-intensive pulmonary rehabilitation for lung cancer patients: is it feasible and effective?Journal of thoracic disease · 2017Article
- The Effectiveness of Electrical Acupuncture Stimulation in Reducing Levels of Self-reported Anxiety of Lung Cancer Patients during Palliative Care: A Pilot Study.Iranian journal of public health · 2017Article
- Induction of GOncology letters · 2016Article
- Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer: A meta-analysis.Thoracic cancer · 2016Article
- Incidence rate of lung cancer in urban Shijiazhuang in 2012 with prevention implication.Thoracic cancer · 2016Article
- Lung cancer incidence and mortality in China, 2011.Thoracic cancer · 2016Article
- Status and Perspectives of Clinical Modes in Surgical Patients With Lung Cancer: A Retrospective Study.Medicine · 2016Article
- Status and perspectives of detection by low-dose computed tomography or computed radiography in surgical patients with lung cancer, based on a five-year study.Thoracic cancer · 2016Article
- China national lung cancer screening guideline with low-dose computed tomography (2015 version).Thoracic cancer · 2015Article
- CHRNA3 genetic polymorphism and the risk of lung cancer in the Chinese Han smoking population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- [Relationship between Clinical Characteristics and Diagnostic Modes of Hospitalized Surgical Patients with Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2015Article
- A meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer.Journal of thoracic disease · 2015Article
- Efficacy and safety of docetaxel for advanced non-small-cell lung cancer: a meta-analysis of Phase III randomized controlled trials.OncoTargets and therapy · 2015Article
- Cytochrome P450 1A1 exon 7 polymorphism and susceptibility to lung cancer in the Chinese population: an updated meta-analysis and review.OncoTargets and therapy · 2015Article
- The TP53 codon 72 Pro/Pro genotype may be associated with an increased lung cancer risk in North China: an updated meta-analysis.International journal of clinical and experimental medicine · 2015Review
- CYP1A1 MspI polymorphism and susceptibility to lung cancer in the Chinese population: an updated meta-analysis and review.International journal of clinical and experimental medicine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe National Central Cancer Registry of China (NCCR) is responsible for cancer surveillance. Local cancer registries in each province submit data for annual publication. The incidence and mortality of lung cancer in China in 2010 by age, gender, and area is reported in this article.
methodsIn 2013, 145 of 219 population-based cancer registries' 2010 data were selected after quality evaluation. Classification included Western, Middle, and Eastern areas, and the crude incidence and mortality rates of lung cancer were calculated by age, gender, and urban and rural. Age-standardized rates were determined by China and World standard population data. The 6th National Population Census data of China was used, combined with the registries' data to estimate the lung cancer burden in China in 2010.
resultsLung cancer had the highest incidence and mortality in China for men and women. It was estimated that 605 946 lung cancer cases were diagnosed in China in 2010, with a crude incidence rate of 46.08/100 000, and 486 555 patients died from lung cancer, with a crude mortality rate of 37.00/100 000. Age-standardized rates for incidence were 35.23/100 000 and 35.04/100 000, respectively. Incidence and mortality rates for lung cancer were higher in men and urban areas than those in women and rural areas, reaching a peak for subjects of 80-84 years old.
conclusionLung cancer has the highest incidence and mortality of all cancers in China, especially for males in urban areas. Our findings justify the need to plan and develop effective interventions, such as air pollution control and smoking deterrents, to control and prevent the spread of lung cancer in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.